Cancer prevention research then and now

Nature Reviews Cancer

Volumn 9, Issue 7, 2009, Pages 508-516

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASBESTOS; BETA CAROTENE; CALCIUM; CELECOXIB; EFLORNITHINE; FINASTERIDE; HEPATITIS B VACCINE; PLACEBO; RALOXIFENE; RETINOL; SELENIUM; SULINDAC; TAMOXIFEN; VITAMIN D; WART VIRUS VACCINE;

ADENOMATOUS POLYP; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER MODEL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLON POLYP; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; HISTORY; HUMAN; LIFESTYLE; LIVER CANCER; LOW DRUG DOSE; LOW FAT DIET; LUNG CANCER; MAMMOGRAPHY; MENOPAUSE; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; REVIEW; RISK REDUCTION; SMOKING; ULTRAVIOLET IRRADIATION; UTERINE CERVIX CANCER; VIRUS ETIOLOGY; VITAMIN SUPPLEMENTATION;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; DIET; HUMANS; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; RESEARCH; ULTRAVIOLET RAYS;

EID: 67649470377     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2646     Document Type: Review

References (136)

1. Danaei, G., Vander Hoorn, S., Lopez, A. D., Murray, C. J. & Ezzati, M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet366, 1784-1793 (2005).
2. Gurunluoglu, R. & Gurunluoglu, A. Paul of Aegina: landmark in surgical progress. World J. Surg. 27, 18-25(2003).
3. Ramazzini, B. De Morbis Artificium Diatriba (translated by Wright, W. C.) (Univ. of Chicago Press, Chicago, 1940).
4. Hill, J. Cautions Against the Immoderate Use of Snuff (Baldwin and Jackson, London, 1761).
5. Pott, P. Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures and the Mortifications of the Toes and Feet (Haves, Clarke and Collins, London, 1 775).
6. Hutchinson, J. On some examples of arsenic-keratosis of the skin and of arsenic-cancer. Trans. Pathol. Soc. Lond. 39,352-393(1888).
7. Rehn, L Bladder tumours in fuchsin workers. Arch. Fuer Klin. Chirurgie 50, 588-600 (1895).
8. Huff, J. Carcinogenicity Testing, Predicting, and Interpreting Chemical Effects (ed. Kitchin, K. T) 21-1 23 (Dekker, New York, 1999).
9. Frieben, A. Demonstration eines Cancroid der rechten Handdruckens das sich nach langdauerneder Einwirkung von Roentgenstrahlen entwickelt hat. Fortschr. Roentgenstr. 6, 106-111 (1902).
10. Sick, H. Karzinom der Haut das auf dem Boden eines Roentgenulcus enstanden its. Muench Med. Wochenschr. 50, 1445 (1902).
11. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397-411 (1911).
12. Yamagiwa, K. & Ichikawa, K. Experimental study of the pathogenesis of carcinoma. CA Cancer J. Clin. 27, 174-181 (1977).
13. Hill, M. J. Changes and developments in cancer prevention.-J. R. Soc. Health 121, 94-97(2001).
14. Gofman, J. W. & O'Connor, E. Cancer in the family: does each case require more than one cause? The likelihood of co-action. Committee for Nuclear Responsibility [online], http://www.ratical.org/radiation/CNR/ CoAction. html (1999).
15. Creech, H. J. Historical review of the American Association of Cancer Research, Inc., 1941-1978. Cancer Res. 39, 1863-1890(1979).
16. Adams, S. H. What can we do about cancer? The most vital and insistent question in the medical world. Ladies Home J. 30, 21-22(1913).
17. Cantor, D. Introduction: cancer control and prevention in the twentieth century. Bull. Hist. Med. 81, 1 -38 (2007).
18. Cantor, D. Cancer, quackery and the vernacular meanings of hope in 1950s America. J. Hist. Med. Allied Sci. 61, 324-368 (2006).
19. Wynder, E. L. & Graham, E. A. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J. Am. Med. Assoc. 143, 329-336(1950).
20. American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. World Cancer Research Fund/American Institute for Cancer Research [online], http://www. dietandcancerreport.org/ (1997).
21. American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund/American Institute for Cancer Research [online], http://www. dietandcancerreport.org/ (2007).
22. Doll, R. & Hill, A. B. Smoking and carcinoma of the lung; preliminary report. BMJ 2, 739-748 (1950).
23. Hammond, E. C. & Horn, D. The relationship between human smoking habits and death rates: a follow-up study of 1 87,766 men. J. Am. Med. Assoc. 155, 1316-1328(1954).
24. Hammond, E. C. & Horn, D. Smoking and death rates; report on forty-four months of follow-up of 187,783 men. II. Death rates by cause. J. Am. Med. Assoc. 166, 1294-1308(1958).
25. Hammond, E. C. & Horn, D. Smoking and death rates; report on forty-four months of follow-up of 187,783 men. I. Total mortality. J. Am. Med. Assoc. 166, 1159-1172(1958).
26. Doll, R. & Hill, A. B. The mortality of doctors in relation to their smoking habits; a preliminary report. BMJ 1, 1451-1455(1954).
27. Doll, R. & HiII, A. B. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. BMJ 2, 1071-1081 (1956).
28. Doll, R., Peto, R., Boreham, J. & Sutherland, I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328, 1519 (2004).
29. Hammond, E. C. Cancer etiology: new prospective epidemiological study. CA Cancer J. Clin. 9, 177-178 (1959).
30. Hammond, E. C. Smoking in relation to mortality and morbidity. Findings in first thirty-four months of followup in a prospective study started in 1959. J. Natl Cancer Inst. 32, 1161-1188(1964).
31. Royal College of Physicians. Smoking and Health (Pitman Medical, London, 1962).
32. Houseman, M. Smoking and health: the 1964 Surgeon General's report as a turning point in the anti-smoking movement. Harvard Health Policy Review 2, 118-126 (2001).
33. Wagner, J. C., Sleggs, C. A. & Marchand, P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 17, 260-271 (1960).
34. IARC (ed.) Tobacco smoke and involuntary smoking. World Health Organization; International Agency for Research on Cancer [online], http://monographsJarc.fr/ ENC/Monographs/vol83/vol ume83.pdf (2002).
35. US Department of Health and Human Services. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Office of the Surgeon General [online], http://www. surgeongeneral.gov/ library/secondhandsrnoke/report/ ful I report, pdf (2006).
36. Leborgne, R. Diagnosis of tumors of the breast by simple roentgenography; calcifications in carcinomas. Am. J. Roentgenol. Radium Ther. 65, 1-11 (1951).
37. Sam, S. Evidence on screening for breast cancer from a randomized trial. Cancer 39, 2772-2782 (1 977).
38. Shapiro, S. Periodic screening for breast cancer: the HIP randomized controlled trial health insurance plan. J. Natl Cancer Inst. Monogr. 27-30 (1997).
39. Lilienfeld, A. M. The relationship of cancer of the female breast to artificial menopause and martial status. Cancer 9, 927-934(1956).
40. Jordan, V. C. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J. Steroid Biochem. 5, 354 (1974).
41. Miki, Y et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science 266,66-71 (1994).
42. Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-1 3. Science 265, 2088-2090 (1994).
43. Papanicolaou, G. New cancer diagnosis. Proceedings of the Third Race Betterment Conference 528-534 (1928).
44. Papanicolaou, G. N. & Traut, H. The diagnostic value of vaginal smears in carcinoma of the uterus. Am. J. Obstet. Gynecol. 42, 193-206 (1941).
45. Wynder, E. L., Cornfield, J., Schroff, P. D. & Doraiswami, K. R. A study of environmental factors in carcinoma of the cervix. Am. J. Obstet. Gynecol. 68, 1016-1047; discussion, 1048-1052(1954).
46. Beral, V Cancer of the cervix: a sexually transmitted infection? Lancet 1, 1037-1040(1974).
47. Hewitt, H. The vast investment in research into the role of viruses in human cancer has largely been wasted because there is still little firm evidence for such a role. Eur. J. Cancer Prev. 1, 187-189(1992).
48. Blumberg, B. S. & London, W. T. Hepatitis B virus and the prevention of primary hepatocellular carcinoma. N. Engl. J. Med. 304, 782-784 (1 981).
49. Durst, M., Gissmann, L, Ikenberg, H. & zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA 80, 3812-3815(1983).
50. Barrasso, R., De Brux, J., Croissant, O. & Orth, G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N. Engl. J. Med. 317,916-923(1987).
51. Schiffman, M. H. et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl Cancer Inst. 85,958-964(1993).
52. Manos, M. M. et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281, 1605-1610(1999).
53. Callaghan, J., Karim, S., Mortlock, S., Wintert, M. & Woodward, N. Hybrid capture as a means of detecting human papillomavirus DNA from liquid-based cytology specimens: a preliminary evaluation. Br. J. Biomed. Sci. 58, 184-189(2001).
54. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
55. Paavonen, J. et al. Efficacy of a prophylactic adjuvanted bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161 -2170 (2007).
56. [No authors listed.] New vaccine prevents cervical cancer. FDA Consum. 40, 37 (2006).
57. Future II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
58. Ault, K. A. Effect of prophylactic human papillomavirus LI virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369, 1861-1868 (2007).
59. Hockberger, P. E. A history of ultraviolet photobiology for humans, animals and microorganisms. Photochem. Photobiol. 76, 561-579 (2002).
60. Findlay, G. M. Ultra-violet light and skin cancer. Lancet 1070-1073 (1928).
61. Bode, A. M. & Dong, Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE 2003, RE2(2003).
62. Epstein, J. H. Photocarcinogenesis, skin cancer, and aging. J. Am. Acad. Dermatol. 9,487-502 (1983).
63. Fitzpatrick, T B., Sober, A. J., Pearson, B. J. & Lew, R. in Research in Photobiology (ed. Castellani, A.) 485-490 (Plenum, New York, 1976).
64. Forbes, P. D., Davis, R. J. & Urbach, F in Research in Photobiology (ed. Castellani, A.) 469-478 (Plenum, New York, 1976).
65. International Agency for Research on Cancer. Solar and ultraviolet radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans [online], http://monographs.iarc.fr/ENG/Monographs/vol55/ volume55.pdf (1992).
66. Kusewitt, D. F, Budge, C. L., Anderson, M. M., Ryan, S. L. & Ley, R. D. Frequency of ultraviolet radiationinduced mutation at the hprt locus in re pair-proficient murine fibroblasts transfected with the denV gene of bacteriophage T4. Photochem. Photobiol. 58, 450-454(1993).
67. Ley, R. D. Photoreactivation in humans. Proc. Natl Acad. Sci. USA 90, 4337 (1 993).
68. Setlow, R. B. The wavelengths in sunlight effective in producing skin cancer: a theoretical analysis. Proc. Natl Acad. Sci. USA 71, 3363-3366 (1974).
69. de Laat, A., van der Leun, J. C. & de Gruijl, F. R. Carcinogenesis induced by UVA (365-nm) radiation: the dose-time dependence of tumor formation in hairless mice. Carcinogenesis 18, 1013-1020 (1997).
70. de Laat, J. M. & de Gruijl, F R. The role of UVA in the aetiology of non-melanoma skin cancer. Cancer Surv. 26, 173-191 (1996).
71. Gasparro, F P. Sunscreens, skin photobiology, and skin cancer: the need for UVA protection and evaluation of efficacy. Environ. Health Perspect. 108 (Suppl. 1), 71-78(2000).
72. Runger, T M. Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer. A short review. Photodermatol. Photoimmunol. Photomed. 15, 212-216(1999).
73. Setlow, R. B. Spectral regions contributing to melanoma: a personal view. J. Investig. Dermatol. Symp. Proc. 4, 46-49 (1999).
74. Greegor, D. H. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 201, 943-945 (1967).
75. Wolff, W. I. Colonoscopy: history and development. Am. J. Gastroenterol. 84, 1017-1025 (1989).
76. Wynder, E. L &Gor¡, G. B. Contribution of the environment to cancer incidence: an epidemiologic exercise. J. Natl Cancer Inst. 58, 825-832 (1977).
77. Doll, R. & Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191-1308 (1981).
78. Committee on Diet, Nutrition, and Cancer. Diet, Nutrition and Cancer. National Research Council [online], htlp://books.nap.edu/catalog.php? record id= 371 toc (1982).
79. Reddy, B. S. et al. Nutrition and its relationship to cancer. Ac/v. Cancer Res. 32, 237-345 (1980).
80. Koop, C. E. The Surgeon General's Report on Nutrition and Health, US Department of Health and Human Services [online], http://profiles.nlm.nih. gOv/NN/B/C/ Q/G/ /nnbcqg.pdf (1988).
81. Wattenberg, L W. Chemoprophylaxis of carcinogenesis: a review. Cancer Res. 26, 1520-1526 (1966).
82. Sporn, M. B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36,2699-2702(1976).
83. Wattenberg, L W. Chemoprevention of cancer. Cancer Res. 45, 1-8(1985).
84. Hong, W. K. & Sporn, M. B. Recent advances in chemoprevention of cancer. Science 278, 1073-1077 (1997).
85. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 90, 1371-1388(1998).
86. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652-1662(2005).
87. Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006).
88. Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
89. Barrett-Connor, E. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137(2006).
90. Thompson, I. M., Klein, E. A., Lippman, S. M., Coltman, C. A. & Djavan, B. Prevention of prostate cancer with finasteride: US/European perspective. Eur. Urol. 44, 650-655 (2003).
91. Kulkami, G. S. et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J. Urol. 175, 505-509(2006).
92. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. (PhilaPa) 1, 174-181 (2008).
93. Pinsky, P., Parnes, H. & Ford, L Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev. Res. (Phila Pa) 1, 1 82-186 (2008).
94. Thun, M. J., Namboodiri, M. M. & Heath, C. W. Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl. J. Med. 325, 1593-1596(1991).
95. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Med. 342, 1946-1 952 (2000).
96. Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873-884(2006).
97. Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895 (2006).
98. Meyskens, F. L. Jr et al. Difluoromethylornithine plus sulindacfor the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prev. Res. (PhilaPa) 1, 32-38 (2008).
99. Sporn, M. B. & Hong, W. K. Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nature Clin. Pract. Oncol. 5, 628-629 (2008).
100. Williams, R. W. The Natural History of Cancer With Special Reference to Its Causation and Prevention (Heinemann, London, 1908).
101. Lambe, W. Water and Vegetable Diet in Consumption, Scrofulla, Cancer, Asthma, and Other Chronic Diseases (Fowlers and Wells, New York, 1854).
102. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330, 1029-1035(1994).
103. Omenn, G. S. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150-1155(1996).
104. Omenn, G. S. et al. The β-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 54, 2038s-2043s (1994).
105. Albanes, D. et al. a-Tocopherol and β-carotene supplements and lung cancer incidence in the alphatocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl Cancer Inst. 88, 1560-1570 (1996).
106. Virtamo, J. et al. Incidence of cancer and mortality following a-tocopherol and ß-carotene supplementation: a postintervention follow-up. JAMA 290, 476-485 (2003).
107. Neuhouser, M. L. et al. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the β-carotene and retinol efficacy trial (CARET). Cancer Epidemiol. Biomarkers Prev. 12, 350-358(2003).
108. Goodman, G. E. et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping ß-carotene and retinol supplements. J. Natl Cancer Inst. 96, 1743-1750 (2004).
109. Taylor, P. R. & Albanes, D. Selenium, vitamin E, and prostate cancer -ready for prime time? J. Natl Cancer Inst. 90, 1184-1185(1998).
110. Brawley, O. W. & Parnes, H. Prostate cancer prevention trials in the USA. Eur. J. Cancer 36, 1312-1315 (2000).
111. Kumar, N. B. & Besterman-Dahan, K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control 6, 580-586 (1999).
112. Lippman, S. M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51 (2009).
113. Alberts, D. S. et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N. Engl. J. Med. 342, 1156-1162(2000).
114. Pierce, J. P. et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) study. ControlClin. Trials 23, 728-756 (2002).
115. Pierce, J. P. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA298, 289-298 (2007).
116. Blackburn, G. L & Wang, K. A. Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). Am. J. Clin. Nutr. 86,s878-s881 (2007).
117. Chlebowski, R. T et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl Cancer Inst. 98, 1767-1776(2006).
118. Pierce, J. P. Diet and breast cancer prognosis: making sense of the Women's Healthy Eating and Living and Women's Intervention Nutrition Study trials. Curr. Opin. Obstet. Gynecol. 21, 86-91 (2009).
119. Cummings, N. B. Women's health and nutrition research: US governmental concerns. J. Am. Coll. Nutr. 12,329-336(1993).
120. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin. Trials 19,61-109(1998).
121. Prentice, R. L et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295, 629-642 (2006).
122. Prentice, R. L. et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J. Natl Cancer Inst. 99, 1534-1543 (2007).
123. Rohan, T. E. et al. Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. Cancer Prev. Res. (Phila Pa) 1, 275-284 (2008).
124. Wactawski-Wende, J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354, 684-696 (2006).
125. Tomatis, L & Huff, J. Evolution of cancer etiology and primary prevention. Environ. Health Perspect. 109, A458-A460(2001).
126. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
127. Food and Drug Administration. Guidance for industry, investigators, and reviewers: exploratory IND studies. Center for Drug Evaluation and Research [online], http://www.fda.gov/cder/guidance/7086fnl.pdf (2006).
128. Kummar, S. et al. Phase O clinical trials: conceptions and misconceptions. Cancer J. 14, 133-137(2008).
129. Doroshow, J. H. & Parchment, R. E. Oncologic phase O trials incorporating clinical pharmacodynamics: from concept to patient. Clin. Cancer Res. 14, 3658-3663 (2008).
130. van den Brandt, P. A., Botterweck, A. A. & Goldbohm, R. A. Salt intake, cured meat consumption, refrigerator use and stomach cancer incidence: a prospective cohort study (Netherlands). Cancer Causes Control 14, 427-438(2003).
131. La Vecchia, C., Franceschi, S. & Levi, F. Epidemiological research on cancer with a focus on Europe. Eur. J. Cancer Prev. 12,5-14(2003) .
132. Tsugane, S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci. 96, 1-6 (2005).
133. Archer, V. E. Latitudinal variation of digestive tract cancers in the US and China. Nutr. Cancer 12, 213-223(1989).
134. Coggon, D., Barker, D. J., Cole, R. B. & Nelson, M. Stomach cancer and food storage. J. Natl Cancer Inst. 81, 1178-1182(1989).
135. Boeing, H. Epidemiological research in stomach cancer progress over the last ten years. J. Cancer Res. Clin. Oncol. 117, 133-143(1991).
136. Cohen, A. J. & Roe, F J. Evaluation of the aetiological role of dietary salt exposure in gastric and other cancers in humans. FoodChem. Toxicol. 35, 271-293 (1997).